Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T15352
|
||||
Former ID |
TTDS00318
|
||||
Target Name |
HIV reverse transcriptase
|
||||
Gene Name |
gag-pol
|
||||
Synonyms |
gag-pol
|
||||
Target Type |
Successful
|
||||
Disease | Breast cancer [ICD9: 174, 175; ICD10: C50] | ||||
Cytomegalovirus infection [ICD10: B25] | |||||
HIV infection; Chronic hepatitis b [ICD9: 042, 070.2-070.3; ICD10: B16, B18.0, B18.1, B20] | |||||
Hepatitis virus infection; Human immunodeficiency virus infection [ICD9:573.3, 279.3; ICD10: K75.9, B20-B26] | |||||
Human immunodeficiency virus infection [ICD9: 279.3; ICD10: B20-B26] | |||||
HIV-1 infection [ICD9: 001-139, 042; ICD10: B20-B24] | |||||
Herpes simplex virus infection [ICD9: 54; ICD10: B00] | |||||
HBV infection [ICD9: 070.2-070.3; ICD10: B16, B18.0, B18.1] | |||||
Mycobacterium tuberculosis infection [ICD10: A15-A19] | |||||
Sexually transmitted infection [ICD10: A64] | |||||
Viral infections [ICD9: 054.0, 054.1, 054.2, 054.3, 075, 771.2, 052, 053; ICD10: B01, B02, A60, B00, B27, G05.1, P35.2] | |||||
Unspecified [ICD code not available] | |||||
Function |
Integrase: Catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre- integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's atthe 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration.
|
||||
Target Validation |
T15352
|
||||
UniProt ID | |||||
Sequence |
PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPV
FAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFKKQNPDIVI YQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWT VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAE LELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGA HTNDVKQLTEAVQKITTESIVIWGKTPKFKLPIQKETWETWWTEYWQATWIPEWEFVNTP PLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNKGRQKVVPLTNTTNQKTELQ AIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVNQIIEQLIKKEKVYLAWVPAHK GIGGNEQVDKLVSAGIRKIL |
||||
Drugs and Mode of Action | |||||
Drug(s) | Abacavir | Drug Info | Approved | Human immunodeficiency virus infection | [550653] |
Adefovir Dipivoxil | Drug Info | Approved | HBV infection | [536414] | |
Delavirdine | Drug Info | Approved | Human immunodeficiency virus infection | [550326] | |
Didanosine | Drug Info | Approved | Human immunodeficiency virus infection | [468066], [536361] | |
Efavirenz | Drug Info | Approved | Human immunodeficiency virus infection | [550326] | |
Emtricitabine | Drug Info | Approved | Hepatitis virus infection; Human immunodeficiency virus infection | [527650], [532210], [536361] | |
Etravirine | Drug Info | Approved | HIV-1 infection | [529941], [536833] | |
Lamivudine | Drug Info | Approved | HIV infection; Chronic hepatitis b | [536361] | |
Nevirapine | Drug Info | Approved | Human immunodeficiency virus infection | [550326] | |
Stavudine | Drug Info | Approved | Human immunodeficiency virus infection | [536361] | |
Tenofovir | Drug Info | Approved | Human immunodeficiency virus infection | [537238] | |
Tenofovir disoproxil fumarate | Drug Info | Approved | Unspecified | [551871] | |
Zalcitabine | Drug Info | Approved | Human immunodeficiency virus infection | [468060], [536361] | |
Zidovudine | Drug Info | Approved | Human immunodeficiency virus infection | [468057], [536361] | |
Apricitabine | Drug Info | Phase 3 | Human immunodeficiency virus infection | [522332] | |
Emtricitabine | Drug Info | Phase 3 | HBV infection | [550812] | |
Glyminox | Drug Info | Phase 3 | Sexually transmitted infection | [521657] | |
MK-1439 | Drug Info | Phase 3 | Human immunodeficiency virus infection | [525133] | |
VM-1500 | Drug Info | Phase 2/3 | Human immunodeficiency virus infection | [525255] | |
Alovudine | Drug Info | Phase 2 | Breast cancer | [524903] | |
Amdoxovir | Drug Info | Phase 2 | HBV infection | [524146] | |
BILR-355 | Drug Info | Phase 2 | Human immunodeficiency virus infection | [521806] | |
EMIVIRINE | Drug Info | Phase 2 | Human immunodeficiency virus infection | [521441] | |
F4co vaccine | Drug Info | Phase 2 | Human immunodeficiency virus infection | [523204], [548656] | |
GS-7340 | Drug Info | Phase 2 | Human immunodeficiency virus infection | [523854] | |
IDX899 | Drug Info | Phase 2 | Human immunodeficiency virus infection | [548635] | |
L-697,661 | Drug Info | Phase 2 | Human immunodeficiency virus infection | [533696] | |
Lersivirine | Drug Info | Phase 2 | Human immunodeficiency virus infection | [523279] | |
NRT inhibitor | Drug Info | Phase 2 | Human immunodeficiency virus infection | [550383] | |
OBP-601 | Drug Info | Phase 2 | HIV-1 infection | [548329] | |
RALURIDINE | Drug Info | Phase 2 | Human immunodeficiency virus infection | [521438], [534371] | |
Ad35-GRIN | Drug Info | Phase 1/2 | Human immunodeficiency virus infection | [524697] | |
Ad35-GRIN/ENV | Drug Info | Phase 1 | Human immunodeficiency virus infection | [523741] | |
AIC-292 | Drug Info | Phase 1 | Human immunodeficiency virus infection | [549111] | |
ATEVIRDINE | Drug Info | Phase 1 | Human immunodeficiency virus infection | [521415] | |
CALANOLIDE A | Drug Info | Phase 1 | Mycobacterium tuberculosis infection | [521471] | |
Capravirine | Drug Info | Phase 1 | Human immunodeficiency virus infection | [521433] | |
CMX-157 | Drug Info | Phase 1 | Human immunodeficiency virus infection | [522964] | |
GW-695634 | Drug Info | Phase 1 | Human immunodeficiency virus infection | [521608] | |
KM-023 | Drug Info | Phase 1 | Human immunodeficiency virus infection | [523464] | |
MK-6186 | Drug Info | Phase 1 | Human immunodeficiency virus infection | [523090] | |
MSH-372 | Drug Info | Phase 1 | Human immunodeficiency virus infection | [524596] | |
TROVIRDINE HYDROCHLORIDE | Drug Info | Phase 1 | Human immunodeficiency virus infection | [545264] | |
UC-781 | Drug Info | Phase 1 | Human immunodeficiency virus infection | [521973], [531646] | |
Lobucavir | Drug Info | Discontinued in Phase 3 | Viral infections | [545123] | |
AZT-P-DDI | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [546009] | |
DMP-961 | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [546920] | |
Elvucitabine | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [546317] | |
FOZIVUDINE TIDOXIL | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [546321] | |
L-696229 | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [544904] | |
Lodenosine | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [545946] | |
Loviride | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [545265] | |
Opaviraline | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [546961] | |
R-18893 | Drug Info | Discontinued in Phase 2 | Human immunodeficiency virus infection | [545122] | |
DPC-082 | Drug Info | Discontinued in Phase 1 | Human immunodeficiency virus infection | [547216] | |
L-697639 | Drug Info | Discontinued in Phase 1 | Human immunodeficiency virus infection | [545121] | |
PNU-142721 | Drug Info | Discontinued in Phase 1 | Human immunodeficiency virus infection | [546794] | |
R-82150 | Drug Info | Discontinued in Phase 1 | Human immunodeficiency virus infection | [545216] | |
R-82913 | Drug Info | Discontinued in Phase 1 | Human immunodeficiency virus infection | [544785] | |
A-79296 | Drug Info | Terminated | Herpes simplex virus infection | [545518] | |
ANX-201 | Drug Info | Terminated | Cytomegalovirus infection | [547232] | |
BAY-Z-4305 | Drug Info | Terminated | HIV-1 infection | [547023] | |
BEA-005 | Drug Info | Terminated | Cytomegalovirus infection | [546573] | |
C-AFG | Drug Info | Terminated | Viral infections | [545472] | |
DMP-963 | Drug Info | Terminated | Human immunodeficiency virus infection | [546921] | |
DPC-A78277 | Drug Info | Terminated | Human immunodeficiency virus infection | [547904] | |
GS-9148 | Drug Info | Terminated | Human immunodeficiency virus infection | [547439] | |
ISIS-1082 | Drug Info | Terminated | Viral infections | [544826] | |
MEN-10690 | Drug Info | Terminated | HIV-1 infection | [546459] | |
MEN-10880 | Drug Info | Terminated | HIV-1 infection | [550069] | |
MEN-10979 | Drug Info | Terminated | HIV-1 infection | [546458] | |
MIV-170 | Drug Info | Terminated | Human immunodeficiency virus infection | [547796] | |
MSC-204 | Drug Info | Terminated | Human immunodeficiency virus infection | [546647] | |
Navuridine | Drug Info | Terminated | Human immunodeficiency virus infection | [544779] | |
RDEA-427 | Drug Info | Terminated | Human immunodeficiency virus infection | [548289] | |
RDEA-640 | Drug Info | Terminated | Human immunodeficiency virus infection | [548289] | |
SPD-756 | Drug Info | Terminated | Human immunodeficiency virus infection | [547094] | |
UC-38 | Drug Info | Terminated | Human immunodeficiency virus infection | [545857] | |
UC-84 | Drug Info | Terminated | Human immunodeficiency virus infection | [545932] | |
Adefovir Dipivoxil | Drug Info | Investigative | Discovery agent | [1572605] | |
Modulator | A-79296 | Drug Info | [550915] | ||
Adefovir Dipivoxil | Drug Info | [556264] | |||
Alovudine | Drug Info | ||||
Amdoxovir | Drug Info | ||||
ANX-201 | Drug Info | ||||
Apricitabine | Drug Info | ||||
ATEVIRDINE | Drug Info | [534208] | |||
AZT nucleotide mimics | Drug Info | ||||
BEA-005 | Drug Info | [543996] | |||
C-AFG | Drug Info | [545473] | |||
Delavirdine | Drug Info | [556264] | |||
E-EBU-dM | Drug Info | ||||
Efavirenz | Drug Info | [556264] | |||
Elvucitabine | Drug Info | ||||
EMIVIRINE | Drug Info | ||||
Emtricitabine | Drug Info | [527650], [532210] | |||
Etravirine | Drug Info | [529941] | |||
IDX899 | Drug Info | ||||
ISIS-1082 | Drug Info | [534318] | |||
L-697,661 | Drug Info | ||||
Lamivudine | Drug Info | [556264] | |||
Lobucavir | Drug Info | ||||
MEN-10690 | Drug Info | [550886] | |||
MEN-10880 | Drug Info | [550886] | |||
MEN-10979 | Drug Info | [534193] | |||
MSC-204 | Drug Info | [550939] | |||
Nevirapine | Drug Info | ||||
Opaviraline | Drug Info | [1572591] | |||
R-18893 | Drug Info | [550873] | |||
R-82150 | Drug Info | ||||
R-82913 | Drug Info | ||||
Tenofovir disoproxil fumarate | Drug Info | [526475], [532210] | |||
TNK-651 | Drug Info | ||||
TROVIRDINE HYDROCHLORIDE | Drug Info | ||||
UC-38 | Drug Info | [534083] | |||
UC-84 | Drug Info | [534721] | |||
Inhibitor | Abacavir | Drug Info | [537321] | ||
AIC-292 | Drug Info | [532460] | |||
AZT-P-DDI | Drug Info | [534200], [551871] | |||
BAY-Z-4305 | Drug Info | [550896] | |||
BILR-355 | Drug Info | [531281], [551871] | |||
CALANOLIDE A | Drug Info | [526066] | |||
Capravirine | Drug Info | [527112] | |||
CMX-157 | Drug Info | [544301] | |||
Didanosine | Drug Info | [537278] | |||
DMP-961 | Drug Info | [544096], [551871] | |||
DMP-963 | Drug Info | [544096], [551871] | |||
DPC-082 | Drug Info | [525645], [551871] | |||
DPC-A78277 | Drug Info | [527188] | |||
FOZIVUDINE TIDOXIL | Drug Info | [531419], [551871] | |||
Glyminox | Drug Info | [527010] | |||
GS-7340 | Drug Info | [527526] | |||
GS-9148 | Drug Info | [529800] | |||
GW-695634 | Drug Info | [528050] | |||
KM-023 | Drug Info | [532985] | |||
L-696229 | Drug Info | [544027], [551871] | |||
L-697639 | Drug Info | [533619] | |||
Lersivirine | Drug Info | [531272] | |||
Lodenosine | Drug Info | [532937] | |||
Loviride | Drug Info | [532362] | |||
MIV-170 | Drug Info | [531011] | |||
MK-1439 | Drug Info | [532619] | |||
MK-6186 | Drug Info | [531832] | |||
MSH-372 | Drug Info | [550939] | |||
Navuridine | Drug Info | [528480] | |||
NRT inhibitor | Drug Info | [530457] | |||
NSC-625487 | Drug Info | [525585], [551871] | |||
OBP-601 | Drug Info | [531951] | |||
PNU-142721 | Drug Info | [531587] | |||
RALURIDINE | Drug Info | [533617], [551871] | |||
RDEA-427 | Drug Info | [550865] | |||
RDEA-640 | Drug Info | [550132] | |||
SPD-756 | Drug Info | [551874] | |||
Stavudine | Drug Info | [535977] | |||
Tenofovir | Drug Info | [535958] | |||
UC-781 | Drug Info | [527689] | |||
VM-1500 | Drug Info | [544439] | |||
Zalcitabine | Drug Info | [535977] | |||
Zidovudine | Drug Info | [535958] | |||
References | |||||
Ref 468057 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4825). | ||||
Ref 468060 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4828). | ||||
Ref 468066 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4833). | ||||
Ref 521415 | ClinicalTrials.gov (NCT00000753) A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC. U.S. National Institutes of Health. | ||||
Ref 521433 | ClinicalTrials.gov (NCT00002214) Phase I Trial of S-1153 in Patients With HIV Infection. U.S. National Institutes of Health. | ||||
Ref 521438 | ClinicalTrials.gov (NCT00002338) The Safety and Effectiveness of 935U83 in HIV-Infected Patients. U.S. National Institutes of Health. | ||||
Ref 521441 | ClinicalTrials.gov (NCT00002413) A Study of MKC-442 in HIV-Positive Patients. U.S. National Institutes of Health. | ||||
Ref 521471 | ClinicalTrials.gov (NCT00005120) The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs. U.S. National Institutes of Health. | ||||
Ref 521608 | ClinicalTrials.gov (NCT00090077) Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults. U.S. National Institutes of Health. | ||||
Ref 521657 | ClinicalTrials.gov (NCT00129532) Trial of SAVVY and HIV in Ghana. U.S. National Institutes of Health. | ||||
Ref 521806 | ClinicalTrials.gov (NCT00294372) Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients. U.S. National Institutes of Health. | ||||
Ref 521973 | ClinicalTrials.gov (NCT00441909) Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide. U.S. National Institutes of Health. | ||||
Ref 522332 | ClinicalTrials.gov (NCT00686270) A Long Term Safety Study of Apricitabine in HIV-infected Patients. U.S. National Institutes of Health. | ||||
Ref 522964 | ClinicalTrials.gov (NCT01080820) A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers. U.S. National Institutes of Health. | ||||
Ref 523090 | ClinicalTrials.gov (NCT01152255) MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2). U.S. National Institutes of Health. | ||||
Ref 523204 | ClinicalTrials.gov (NCT01218113) Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naive HIV-1 Infected Persons. U.S. National Institutes of Health. | ||||
Ref 523279 | ClinicalTrials.gov (NCT01254656) A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022. U.S. National Institutes of Health. | ||||
Ref 523464 | ClinicalTrials.gov (NCT01348516) Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023. U.S. National Institutes of Health. | ||||
Ref 523741 | ClinicalTrials.gov (NCT01496989) Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers. U.S. National Institutes of Health. | ||||
Ref 523854 | ClinicalTrials.gov (NCT01565850) Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults. U.S. National Institutes of Health. | ||||
Ref 524146 | ClinicalTrials.gov (NCT01738555) A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. U.S. National Institutes of Health. | ||||
Ref 524596 | ClinicalTrials.gov (NCT02033109) Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use. U.S. National Institutes of Health. | ||||
Ref 524697 | ClinicalTrials.gov (NCT02099994) Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults. U.S. National Institutes of Health. | ||||
Ref 524903 | ClinicalTrials.gov (NCT02232581) Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure. U.S. National Institutes of Health. | ||||
Ref 525133 | ClinicalTrials.gov (NCT02403674) Comparison of MK-1439A and ATRIPLA in Treatment-Naive Human Immunodeficiency Virus (HIV)-Infected Participants (MK-1439A-021). U.S. National Institutes of Health. | ||||
Ref 525255 | ClinicalTrials.gov (NCT02489461) Efficacy, Safety and Optimal Dose Selection VM-1500 in Comparison to Efavirenz When Added to Standard-of-care Antiretroviral Therapy. | ||||
Ref 527650 | Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today (Barc). 2005 Apr;41(4):241-52. | ||||
Ref 531646 | First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One. 2011;6(9):e23243. | ||||
Ref 533696 | A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 1993 Oct 7;329(15):1065-72. | ||||
Ref 534371 | Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 1996 Dec;40(12):2842-7. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 536414 | Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2007 May;7(5):751-61. | ||||
Ref 537238 | Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother. 2009;19(4):165-76. | ||||
Ref 544779 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001006) | ||||
Ref 544785 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001064) | ||||
Ref 544826 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001244) | ||||
Ref 544904 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001460) | ||||
Ref 545121 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002199) | ||||
Ref 545122 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002204) | ||||
Ref 545123 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002213) | ||||
Ref 545216 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002478) | ||||
Ref 545264 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002628) | ||||
Ref 545265 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002631) | ||||
Ref 545472 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003394) | ||||
Ref 545518 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003585) | ||||
Ref 545857 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005073) | ||||
Ref 545932 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005397) | ||||
Ref 545946 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005453) | ||||
Ref 546009 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005869) | ||||
Ref 546317 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007421) | ||||
Ref 546321 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007452) | ||||
Ref 546458 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008234) | ||||
Ref 546459 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008240) | ||||
Ref 546573 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008999) | ||||
Ref 546647 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009440) | ||||
Ref 546794 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010327) | ||||
Ref 546920 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011150) | ||||
Ref 546921 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011151) | ||||
Ref 546961 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011603) | ||||
Ref 547023 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012173) | ||||
Ref 547094 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013016) | ||||
Ref 547216 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014106) | ||||
Ref 547232 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014324) | ||||
Ref 547439 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016343) | ||||
Ref 547796 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019379) | ||||
Ref 547904 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020281) | ||||
Ref 548289 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024208) | ||||
Ref 548329 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024698) | ||||
Ref 548635 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027243) | ||||
Ref 548656 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027409) | ||||
Ref 549111 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032413) | ||||
Ref 550069 | [Abstract Book Vol. 2, International Conference on AIDS (10th: 1994: Yokohama, Japan)], International AIDS Society, 1994. | ||||
Ref 525585 | Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir Chem Chemother. 1999 Jul;10(4):211-7. | ||||
Ref 525645 | Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999 Dec;43(12):2893-7. | ||||
Ref 526066 | Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. BETA. 1999 Apr;12(2):8-9. | ||||
Ref 526475 | Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther. 2002 Oct;24(10):1515-48. | ||||
Ref 527112 | Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98. | ||||
Ref 527188 | The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab Dispos. 2004 Dec;32(12):1359-69. Epub 2004 Aug 27. | ||||
Ref 527526 | Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005 May;49(5):1898-906. | ||||
Ref 527650 | Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today (Barc). 2005 Apr;41(4):241-52. | ||||
Ref 527689 | The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79(17):11179-86. | ||||
Ref 528050 | Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35. | ||||
Ref 528480 | Synthesis and anti-human immunodeficiency virus (HIV-1) activity of 3'-deoxy-3'-(triazol-1-yl)thymidines and 2',3'-dideoxy-3'-(triazol-1-yl)uridines and inhibition of reverse transcriptase by their 5'-triphosphates. Chem Pharm Bull (Tokyo). 1990 Sep;38(9):2597-601. | ||||
Ref 529800 | Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009 Jan;53(1):150-6. | ||||
Ref 530457 | Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem. 2009 Dec 18;284(51):35681-91. | ||||
Ref 531011 | Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem Pharmacol. 2010 Oct 15;80(8):1133-40. | ||||
Ref 531272 | Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther.2010 Oct;32(11):1889-95. | ||||
Ref 531281 | Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8. | ||||
Ref 531419 | Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection. J Vet Intern Med. 2011 May-Jun;25(3):413-8. | ||||
Ref 531587 | Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721. Protein Sci. 2011 Oct;20(10):1713-9. | ||||
Ref 531832 | Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35. | ||||
Ref 531951 | Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8. | ||||
Ref 531994 | A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. | ||||
Ref 532362 | Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. | ||||
Ref 532460 | In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9. | ||||
Ref 532619 | Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett. 2014 Feb 1;24(3):917-22. | ||||
Ref 532937 | 2?,3?-Dialdehyde of ATP, ADP, and adenosine inhibit HIV-1 reverse transcriptase and HIV-1 replication. Curr HIV Res. 2014;12(5):347-58. | ||||
Ref 532985 | Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects. Drug Des Devel Ther. 2014 Sep 26;8:1613-9. | ||||
Ref 533617 | 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603. | ||||
Ref 533619 | Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor. Int J Clin Pharmacol Res. 1994;14(2):45-50. | ||||
Ref 534083 | Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Ther. 1996 Jan;276(1):298-305. | ||||
Ref 534193 | New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res. 1996 May;30(2-3):109-24. | ||||
Ref 534200 | Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral Res. 1996 Jun;31(1-2):115-20. | ||||
Ref 534208 | J Med Chem. 1996 Sep 13;39(19):3769-89.Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reversetranscriptase inhibitors. | ||||
Ref 534318 | Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology. 1997 Jan 15;116(1-3):77-88. | ||||
Ref 534721 | Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry. 1998 Oct 13;37(41):14394-403. | ||||
Ref 535977 | Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705. | ||||
Ref 537278 | The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304. | ||||
Ref 537321 | Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only? Curr HIV Res. 2009 May;7(3):320-6. | ||||
Ref 543996 | Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2). J Virol. 2000 October; 74(20): 9771-9775. | ||||
Ref 544027 | L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.. Antimicrob Agents Chemother. 1992 May; 36(5): 1019-1023. | ||||
Ref 544096 | Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer. AAPS PharmSciTech. 2000 December; 1(4): 55-61. | ||||
Ref 544301 | Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol. 2012 Autumn; 9(3): e183-e193. | ||||
Ref 544439 | 127??afety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients. J Acquir Immune Defic Syndr. 2014 April; 65(Suppl 2): 52. | ||||
Ref 545473 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003394) | ||||
Ref 550865 | CN patent application no. 103360398, Triazolopyrimidine hiv-1 retrovirus inhibitor and its preparation method and application thereof. | ||||
Ref 550886 | US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes. | ||||
Ref 550896 | US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases. | ||||
Ref 550915 | US patent application no. 5,830,759, Unique associated kaposi's sarcoma virus sequences and uses thereof. | ||||
Ref 550939 | WO patent application no. 2004,0290,42, Pyrazole derivatives as reverse transcriptase inhibitors. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.